An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections

Nature Medicine

Volumn 8, Issue 12, 2002, Pages 1398-1404

  Kotb, Malak ^a,b   Norrby Teglund, Anna ^a,c   McGeer, Allison ^d   El Sherbini, Hesham ^a,b   Tevik Dorak, M ^a,b   Khurshid, Ayesha ^a,b   Green, Karen ^d   Peeples, Jeanie ^a,b   Wade, Judy ^d   Thomson, Glenys ^e   Schwartz, Benjamin ^f   Low, Donald E ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; SUPERANTIGEN;

ADULT; ALLELISM; ARTICLE; BACTERIAL STRAIN; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; IMMUNOGENETICS; MALE; MOLECULAR BIOLOGY; PHARYNGITIS; PRIORITY JOURNAL; REGULATORY MECHANISM; RISK ASSESSMENT; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; TOXIC SHOCK SYNDROME;

BACTERIA (MICROORGANISMS); POSIBACTERIA; STREPTOCOCCUS; STREPTOCOCCUS SP. 'GROUP A';

EID: 0036908653     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1202-800     Document Type: Article

References (23)

1. Low, D.E., Schwartz, B. & McGeer, A. The re-emergance of severe group A streptococcal disease: An evolutionary perspective, in Emerging Pathogens Vol. 7 (ASM Press, Washington, DC, 1998).
2. Davies, H.D. et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N. Engl. J. Med. 335, 547-554 (1996).
3. Basma, H. et al. Risk factors in the pathogenesis of invasive group A streptococcal infections: Role of protective humoral immunity. Infect. Immun. 67, 1871-1877 (1999).
4. Chatellier, S. et al. Genetic relatedness and superantigen expression of M type 1 group A streptococcal isolates from severe and nonsevere invasive disease. Infect. Immun. 68, 3523-3534 (2000).
5. Kotb, M. Bacterial exotoxins as superantigens. Clin. Microbiol. Rev. 8, 411-426 (1995).
6. Watanabe-Ohnishi, R. et al. Selective depletion of V -bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. J. Infect. Dis. 171, 74-84 (1995).
7. Norrby-Teglund, A. et al. Evidence for superantigen involvement in severe group A streptococcal tissue infections. J. Infect. Dis. 184, 853-860 (2001).
8. Norrby-Teglund, A. et al. Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection. Eur. J. Immunol. 30, 3247-3255 (2000).
9. Hill, A.V. Genetics and genomics of infectious disease susceptibility. Br. Med. Bull. 55, 401-413 (1999).
10. Herman, A., Croteau, G., Sekaly, R.P., Kappler, J. & Marrack, P. HLA-DR alleles differ in their ability to present staphylococcal enterotoxins to T cells. J. Exp. Med. 172, 709-717 (1990).
11. Kaul, R., McGeer, A., Low, D.E., Green, K. & Schwartz, B. Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am. J. Med. 103, 18-24 (1997).
12. Olerup, O. & Zetterquist, H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39, 2253 (1992).
13. Guedez, Y. et al. HLA class II associations with rheumatic heart disease are more evident and consistent among clinically homogeneous patients. Circulation 99, 2784-2790 (1999).
14. Wade, J., NG, EM, & Pellett, F. Caucasian Canadian normal, in HLA 1998 (ed. Gjertson, D.W. & Terasaki, P.I.) (American Society for Histocompatibility and Immunogenetics, Lenexa, 1998).
15. Kaul, R. et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - A comparative observational study. The Canadian Streptococcal Study Group. Clin. Infect. Dis. 28, 800-807 (1999).
16. Dorak, M.T. et al. TNF microsatellites and streptococcal toxic shock syndrome. Hum. Immunol. 62 (Suppl. 1): S30 (2001).
17. Colman, G., Tanna, A., Efstratiou, A. & Gaworzewska, E.T. The serotypes of Streptococcus pyogenes present in Britain during 1980-1990 and their association with disease. J. Med. Microbiol. 39, 165-178 (1993).
18. Stromberg, A., Romanus, V. & Burman, L.G. Outbreak of group A streptococcal bacteremia in Sweden: An epidemiologic and clinical study. J. Infect. Dis. 164, 595-598 (1991).
19. Martin, P.R. & Hoiby, E.A. Streptococcal serogroup A epidemic in Norway 1987-1988. Scand. J. Infect. Dis. 22, 421-429 (1990).
20. Hoge, C.W. et al. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective population-based study. JAMA 269, 384-389 (1993).
21. Norrby-Teglund, A., Lustig, R. & Kotb, M. Differential induction of Th1 versus Th2 cytokines by group A streptococcal toxic shock syndrome isolates. Infect. Immun. 65, 5209-5215 (1997).
22. Newton, D.W. et al. Mutations in the MHC class II binding domains of staphylococcal enterotoxin A differentially affect T cell receptor V_ specificity. J. Immunol. 157, 3988-3994 (1996).
23. Ohnishi, H. et al. CD28 cross-linking augments TCR-mediated signals and costimulates superantigen responses. J. Immunol. 154, 3180-3193 (1995).